A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

Vivacelle Bio

Status and phase

Not yet enrolling

Phase 3

Conditions

Hypovolemia

Septic Shock

Sepsis

Treatments

Drug: VBI-S

Study type

Interventional

Funder types

Industry

Identifiers

NCT06072430

VBI-S-02

Details and patient eligibility

About

This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

Full description

PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

STUDY TREATMENT Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs. When hypotension due to sepsis cannot be reversed with the infusion of fluids the patient is in a state of septic shock. Septic shock is therefore an acute medical emergency and delayed therapy can lead to organ injury. VBI-S is intended to raise blood pressure in patients with septic shock.

Randomization and blinding: This is a randomized, controlled, open-label study and blinding is not applicable to this study.

Data Safety Monitoring Board: A Data Safety Monitoring Board (DSMB) will review the study data.

Enrollment

46 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female at least 18 years of age.
Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection and/or an elevated procalcitonin of ≥ 2 ng/ml.
Patient has a mean blood pressure < 65 mmHg that is unresponsive to fluids currently available on the market.
Sequential Organ Failure Assessment (SOFA) score ≥ 5
Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:
- Lactate > 2 mmol/L
- Fever > 38.3°C, or 101°F
- Hypothermia < 36°C core temperature (<96.8°F)
- Heart rate > 90
- Tachypnea (respiratory rate ≥ 20/min)
- White blood cell count >12,000 or less than 4,000, or with >10% "bands" (immature forms)
- Elevated procalcitonin in serum (≥ 2ng/ml)
- Arterial hypoxemia (PaO2/FiO2 < 300)
- Creatinine increase > 0.5 mg/dL since hospital admission
- INR > 1.5 or aPTT > 60 seconds
Documented dysregulated host response to an infection as indicated by an increase in SOFA score by ≥ 2 points after an infection per the SEPSIS 3 guideline.
Receiving vasopressors to maintain the target MAP of 65 mmHg.

Exclusion criteria

Patients with a ventricular assist device
Acute coronary syndrome
Pregnant
Acute bronchospasm
Acute Mesenteric ischemia
Emergency major surgery
Diagnosis of acute Hepatitis B or C.
Hematologic or coagulation disorders including thrombocytopenia (platelet count <50,000) and associated with hemodynamically significant active bleeding that causes a decrease in blood pressure.
White blood cell count of < 1000 mm3
Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs are for COVID-19.
Patients with a known allergy to soybeans or eggs
Patient is hypervolemic with assessment by physician or physician extender ultrasound 12 hours before infusion of VBI-S if hypervolemia is suspected.
Patient expected to expire within 12 hours.
Patients with disturbances in normal fat metabolism such as pathologic hyperlipemia, lipid nephrosis, or acute pancreatitis with hyperlipidemia.